Vice President, Commercialization Strategies, Consulting & Industry Affairs
Rina Wolf is a nationally recognized expert in the field of laboratory commercialization and reimbursement, with over 20 years of experience in the diagnostic laboratory industry, specializing in Molecular Diagnostic Laboratories. She lectures extensively on these topics and has consulted for over 50 laboratories in the areas of commercialization, optimizing reimbursement and coverage, and compliance.Rina is an active participant and advocate in industry affairs. She is a member of relevant AMA workgroups, is a former President and board member of the California Clinical Laboratory Association and is an active participant with the ACLA (American Clinical Laboratory Association), AMA and the Personalized Medicine Coalition. Rina also advises and presents to investor audiences, recent speaking engagements include William Blair, UBS, Piper Jaffray, Cowen Group, Macquarie and Bloomberg's G2 Intelligence Lab Investment Forum. She has also been a guest lecturer at ASU International School of Diagnostics.Prior to joining XIFIN, Rina was responsible for creating and implementing successful reimbursement strategies with executive positions in the area of commercialization and reimbursement at RedPath Integrated Pathology, Inc., Genomic Health, Inc., and Esoterix (now LabCorp). Rina has a Bachelor of Arts degree from UCLA and a Masters of HealthCare Administration.